Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas.
Metrics to compare | SLRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −3.2x | −0.6x | |
PEG Ratio | - | 0.01 | 0.00 | |
Price/Book | −4.1x | 1.9x | 2.6x | |
Price / LTM Sales | - | 8.9x | 3.3x | |
Upside (Analyst Target) | - | 187.1% | 40.2% | |
Fair Value Upside | Unlock | 4.2% | 5.1% | Unlock |